Learn Why The Bull Case For OPKO Health Stock Could Change Following Quarterly Net Loss

Simply Wall St.11-05

OPKO Health reported third quarter 2026 revenue of US$65.41 million compared with US$56.43 million a year earlier, alongside a net loss of US$53.53 million that contrasted with net income of US$21.63 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681216140?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790","is_english":true,"pubTime":"2026-11-05 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681216140","market":"us","top_or_hot":-1,"title":"Learn Why The Bull Case For OPKO Health Stock Could Change Following Quarterly Net Loss","media":"Simply Wall St.","content":"<div>\n<p>OPKO Health reported third quarter 2026 revenue of US$65.41 million compared with US$56.43 million a year earlier, alongside a net loss of US$53.53 million that contrasted with net income of US$21.63 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-opk/opko-health/news/learn-why-the-bull-case-for-opko-health-stock-could-change-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Learn Why The Bull Case For OPKO Health Stock Could Change Following Quarterly Net Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLearn Why The Bull Case For OPKO Health Stock Could Change Following Quarterly Net Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-05 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-opk/opko-health/news/learn-why-the-bull-case-for-opko-health-stock-could-change-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>OPKO Health reported third quarter 2026 revenue of US$65.41 million compared with US$56.43 million a year earlier, alongside a net loss of US$53.53 million that contrasted with net income of US$21.63 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-opk/opko-health/news/learn-why-the-bull-case-for-opko-health-stock-could-change-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPK","symbol_name":"Opko Health","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-opk/opko-health/news/learn-why-the-bull-case-for-opko-health-stock-could-change-f","article_id":"2681216140","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-opk/opko-health/news/learn-why-the-bull-case-for-opko-health-stock-could-change-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681216140","pubTimestamp":1793878823,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 5, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPK":"Opko Health","BK4139":"生物科技","BK4196":"保健护理服务"},"translate_title":"了解为什么 OPKO Health 股票的牛市在季度净亏损后可能会发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPK":1.5},"content_text":"OPKO Health reported third quarter 2026 revenue of US$65.41 million compared with US$56.43 million a year earlier, alongside a net loss of US$53.53 million that contrasted with net income of US$21.63 million in the prior year period. The business showed higher revenue for both the quarter and the first nine months of 2026, yet losses widened on a per share basis in the quarter, which points to ongoing cost and profitability pressures despite top line progress. This raises questions about how OPKO Health's investment narrative is influenced by rising revenue alongside a return to a quarterly net loss.  Scan beyond OPKO Health and compare its latest loss making quarter with a curated 31 resilient stocks with low risk scores that aims for steadier financial profiles. AdvertisementOPKO Health Investment Narrative Recap To own OPKO Health, you have to believe the pivot toward pharmaceuticals, ModeX antibodies and partnered programs can eventually carry the weight of the group. The latest quarter shows that revenue sits higher than a year ago while the business still reported a sizeable loss. That combination keeps the spotlight on cost discipline and cash use. The most important short term catalyst remains execution on the pipeline and key collaborations that can move OPKO Health closer to covering its expense base. The biggest risk is simple. Losses persist and operating cash flow stays weak, which this quarter did little to ease. The third quarter 2026 earnings release on 4 November is the announcement that really matters here. It sets the current scorecard. Revenue for the quarter reached US$65.41 million compared with US$56.43 million a year earlier, while the period swung from net income of US$21.63 million to a net loss of US$53.53 million. Over nine months, OPKO Health reported revenue of US$206.46 million versus US$159.24 million a year ago and a loss of US$116.8 million compared with a loss of US$194.42 million. Loss per share narrowed over nine months but widened in the quarter, so the operational story still turns on whether management can align expenses with this higher revenue base. What The Current Forecasts Assume For OPKO Health OPKO Health's narrative projects US$628.3 million revenue and US$39.7 million earnings by 2029. That path reflects analyst assumptions of 2.2% yearly revenue growth and an earnings swing of about US$112.6 million from earnings today of a US$72.9 million loss. Uncover how OPKO Health's fair value points to a 134% potential upside to its current price, which could narrow quickly if sentiment shifts. NasdaqGS:OPK 1-Year Stock Price Chart Exploring Other Perspectives One optimistic twist in the alternate view is the expectation that ModeX milestones and royalty streams could meaningfully reshape OPKO Health’s earnings story. The most bullish analysts were penciling in around US$623.6 million to US$628.3 million in 2029 revenue and roughly US$39 million in earnings before this quarter’s loss, so you might see those projections and opinions shift as fresh data is absorbed. Explore 2 other OPKO Health fair value estimates, including one that suggests as much as 380% above the current price! The Verdict Is Yours Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own research and judgment.  A great starting point for your OPKO Health research is our analysis highlighting 2 important warning signs that could impact your investment decision. See our latest analysis for OPKO Health. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate OPKO Health's overall financial health at a glance.  Looking For More Investment Ideas Beyond OPKO Health? If OPKO Health's profile has you reassessing risk, it can help to line it up against other businesses with different balance sheets, income patterns and payout approaches using the Simply Wall St Screener.  If you prefer steadier balance sheets and fewer financial surprises, start with companies in the 31 resilient stocks with low risk scores and see how they compare with OPKO Health's risk profile. If you are hunting for companies with solid finances that still trade below many investors' radars, scan the 19 high quality undiscovered gems and build a watchlist of fresh ideas. If you are looking to tilt your portfolio toward potential value opportunities with stronger fundamentals, review the 35 high quality undervalued stocks and see which stocks warrant a closer look.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681216140","isCrawlerRequest":true}